100 Recruiting Studies Using Fludarabine
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Fludarabine
Delayed Tolerance Through Mixed Chimerism
π Massachusetts General Hospital β Boston, Massachusetts
Kidney Failure
View Study & Checklist βItacitinib for the Prevention of Graft Versus Host Disease
π M D Anderson Cancer Center β Houston, Texas
Hematologic and Lymphocytic Disorder
View Study & Checklist βA Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
π M D Anderson Cancer Center β Houston, Texas
Solid Tumor
View Study & Checklist βLisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
π City of Hope Medical Center β Duarte, California
Recurrent Transformed Chronic Lymphocytic Leukemia
View Study & Checklist βGFRΞ±4 CAR T Cells in MTC Patients
π University of Pennsylvania β Philadelphia, Pennsylvania
Metastatic Medullary Thyroid Cancer
View Study & Checklist βA Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
π Children's Hospital of Central California β Madera, California
Acute Myeloid Leukemia
View Study & Checklist βDose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
π MD Anderson Cancer Center β Houston, Texas
Colorectal Cancer
View Study & Checklist βA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
π Local Institution - 0011 β Birmingham, Alabama
Multiple Sclerosis
View Study & Checklist βRadiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
π University of Chicago β Chicago, Illinois
Dyskeratosis Congenita
View Study & Checklist βA Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
π Local Institution - 0131 β Los Angeles, California
Multiple Myeloma
View Study & Checklist βTotal Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
π City of Hope Medical Center β Duarte, California
Acute Lymphoblastic Leukemia
View Study & Checklist βA Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
π Banner MD Anderson Cancer Center β Gilbert, Arizona
Multiple Myeloma
View Study & Checklist βTBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
π Moffitt Cancer Center β Tampa, Florida
Squamous Cell Carcinoma of Head and Neck
View Study & Checklist βHer2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
π Houston Methodist Hospital β Houston, Texas
Sarcoma
View Study & Checklist βCARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
π Hospital of the Universithy of Pennsylvania β Philadelphia, Pennsylvania
Idiopathic Inflammatory Myopathies
View Study & Checklist βPhase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
π Lineberger Comprehensive Cancer Center β Chapel Hill, North Carolina
Epithelial Ovarian Cancer
View Study & Checklist βA Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
π MD Anderson Cancer Center β Houston, Texas
Advanced Solid Tumor
View Study & Checklist βAllogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
π Masonic Cancer Center, University of Minnesota β Minneapolis, Minnesota
SCID
View Study & Checklist βNeoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
π Ohio State University Comprehensive Cancer Center β Columbus, Ohio
Locally Advanced Melanoma
View Study & Checklist βStudy of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies
π Lucile Packard Children's Hospital Stanford University β Palo Alto, California
B Acute Lymphoblastic Leukemia
View Study & Checklist βStudy of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
π Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill β Chapel Hill, North Carolina
Lymphoma
View Study & Checklist βA Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
π Memorial Sloan Kettering Cancer Center β New York, New York
Acute Myeloid Leukemia (AML)
View Study & Checklist βA Phase 1/2 Trial of ADI-270 in ccRCC
π Adicet Clinical Trials β Redwood City, California
Clear Cell Renal Cell Carcinoma
View Study & Checklist βMaster Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
π City of Hope National Medical Center β Duarte, California
Neoplasms
View Study & Checklist βVenetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
π Dana-Farber Cancer Institute β Boston, Massachusetts
Acute Myeloid Leukemia (AML)
View Study & Checklist β90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
π City of Hope Medical Center β Duarte, California
Acute Lymphoblastic Leukemia
View Study & Checklist βA Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
π Beth Isreal Deaconess Medical Center β Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist βPilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
π National Institutes of Health Clinical Center β Bethesda, Maryland
DOCK8 Deficiency
View Study & Checklist βA Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
π Local Institution - 0106 β Phoenix, Arizona
Lupus Erythematosus, Systemic
View Study & Checklist βAutologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
π City of Hope β Duarte, California
CLL/SLL
View Study & Checklist βPSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
π City of Hope Medical Center β Duarte, California
Castration-Resistant Prostate Carcinoma
View Study & Checklist βStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
π Princess Margaret Cancer Centre β Toronto, Ontario
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients
View Study & Checklist βPeritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Primary Myelofibrosis
View Study & Checklist βBusulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
π M D Anderson Cancer Center β Houston, Texas
Hematopoietic and Lymphoid Cell Neoplasm
View Study & Checklist βFT819 in Subjects With B-cell Malignancies
π University of Alabama at Birmingham β Birmingham, Alabama
Lymphoma, B-Cell
View Study & Checklist βCART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
π University of Pennsylvania β Philadelphia, Pennsylvania
Glioblastoma
View Study & Checklist βAnti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
π University of California, San Francisco β San Francisco, California
Refractory Multiple Myeloma
View Study & Checklist βStudy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
π City of Hope (City of Hope National Medical Center, City of Hope Medical Center) β Duarte, California
Relapsed/Refractory Follicular Lymphoma
View Study & Checklist βA Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Recurrent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist βAdministration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
π Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill β Chapel Hill, North Carolina
Acute Lymphoblastic Leukemia
View Study & Checklist βLymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
π The University of Texas MD Anderson Cancer Center β Houston, Texas
Melanoma
View Study & Checklist βCART-PSMA-TGFΞ²RDN Cells for Castrate-Resistant Prostate Cancer
π University of Pennsylvania β Philadelphia, Pennsylvania
Prostate Cancer
View Study & Checklist βCytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
π M D Anderson Cancer Center β Houston, Texas
Acute Lymphoblastic Leukemia
View Study & Checklist βA Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
π UCSF β San Francisco, California
Multiple Myeloma
View Study & Checklist βHLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
π City of Hope National Medical Center β Duarte, California
Acute Lymphoblastic Leukemia
View Study & Checklist βTocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
π Weill Cornell Medical College β New York, New York
Hematologic Malignancy
View Study & Checklist βSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
π Loma Linda University Cancer Center β Loma Linda, California
Acute Myeloid Leukemia
View Study & Checklist βGenetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
π M D Anderson Cancer Center β Houston, Texas
Metastatic Melanoma
View Study & Checklist βRuxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Aplastic Anemia
View Study & Checklist βStudy to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
π University of Alabama Hospital β Birmingham, Alabama
High-risk Large B-cell Lymphoma (LBCL)
View Study & Checklist βCyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
π Memorial Sloan Kettering Cancer Center β New York, New York
Solid Tumors
View Study & Checklist βA Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
π Local Institution - 111 β Santa Monica, California
Lymphoma, Non-Hodgkin
View Study & Checklist βA Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Lymphoma
View Study & Checklist βTrial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
π National Institutes of Health Clinical Center β Bethesda, Maryland
Chronic Lymphocytic Leukemia
View Study & Checklist βSafety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
π City of Hope β Duarte, California
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
View Study & Checklist βTCRΞ±Ξ²-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
π St. Jude Children's Research Hospital β Memphis, Tennessee
Acute Lymphoblastic Leukemia (ALL)
View Study & Checklist βAdoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
π UPMC Hillman Cancer Center β Pittsburgh, Pennsylvania
Gastric Cancer
View Study & Checklist βAntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
π Washington University School of Medicine β St Louis, Missouri
Non-Hodgkin Lymphoma
View Study & Checklist βTrial Evaluating MGTA-456 in Patients With High-Risk Malignancy
π Masonic Cancer Center at University of Minnesota β Minneapolis, Minnesota
Acute Myeloid Leukemia
View Study & Checklist βGiving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
π Memorial Sloan Kettering Cancer Center β New York, New York
Hematologic Malignancies
View Study & Checklist βMost Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
π Houston Methodist Hospital β Houston, Texas
Hodgkin Disease
View Study & Checklist βEarly Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
π Children's Hospital of Alabama β Birmingham, Alabama
Sickle Cell Disease
View Study & Checklist βChemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
π Roswell Park Cancer Institute β Buffalo, New York
Acute Myeloid Leukemia in Remission
View Study & Checklist βLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
π M D Anderson Cancer Center β Houston, Texas
Bone Sarcoma
View Study & Checklist βMT2017-45: CAR-T Cell Therapy for Heme Malignancies
π Masonic Cancer Center at University of Minnesota β Minneapolis, Minnesota
Acute Lymphoblastic Leukemia
View Study & Checklist βAxi-cel in CNS Lymphoma
π Dana Farber Cancer Institute β Boston, Massachusetts
Lymphoma
View Study & Checklist βCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
π Stanford University, School of Medicine β Palo Alto, California
B Acute Lymphoblastic Leukemia
View Study & Checklist βCD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission
π City of Hope Medical Center β Duarte, California
B Acute Lymphoblastic Leukemia
View Study & Checklist βPhase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
π City of Hope Comprehensive Cancer Center β Duarte, California
Hodgkin Lymphoma, Adult
View Study & Checklist βHighest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
π Children's Hospital of Alabama β Birmingham, Alabama
Acute Myeloid Leukemia Post Cytotoxic Therapy
View Study & Checklist βA Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
π National Institutes of Health Clinical Center β Bethesda, Maryland
Chronic Lymphocytic Leukemia
View Study & Checklist βGenetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
π Chao Family Comprehensive Cancer Center University of California, Irvine β Orange, California
Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist βStudy of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
π Rady Children's Hospital-San Diego β San Diego, California
Acute Leukemia of Ambiguous Lineage in Relapse
View Study & Checklist βCombination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
π City of Hope Medical Center β Duarte, California
Secondary Myelofibrosis
View Study & Checklist βStudy of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
π University of Illinois at Chicago β Chicago, Illinois
Acute Myeloid Leukemia
View Study & Checklist βGenetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
π City of Hope Medical Center β Duarte, California
Adult Acute Myeloid Leukemia in Remission
View Study & Checklist βA Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
π University of Alabama at Birmingham β Birmingham, Alabama
Severe Aplastic Anemia
View Study & Checklist βCAR- PRISM (PRecision Intervention Smoldering Myeloma)
π Dana Farber Cancer Institute β Boston, Massachusetts
Multiple Myeloma
View Study & Checklist βPhase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
π MD Anderson Cancer Center β Houston, Texas
Tumor
View Study & Checklist βEvaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
π University of Iowa/Holden Comprehensive Cancer Center β Iowa City, Iowa
Non Hodgkin Lymphoma
View Study & Checklist βEvaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
π St. Jude Children's Research Hospital β Memphis, Tennessee
Acute Lymphoblastic Leukemia, in Relapse
View Study & Checklist βTriPRIL CAR T Cells in Multiple Myeloma
π Massachusetts General Hospital Cancer Center β Boston, Massachusetts
Multiple Myeloma
View Study & Checklist βHaplocompatible Transplant Using TCRΞ±/Ξ² Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
π St. Jude Children's Research Hospital β Memphis, Tennessee
Severe Combined Immunodeficiency
View Study & Checklist βHuman AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
π University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center β Cleveland, Ohio
Non Hodgkin Lymphoma
View Study & Checklist βIntraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
π University of Minnesota Masonic Cancer Center β Minneapolis, Minnesota
Gynecologic Cancer
View Study & Checklist βA Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
π University of Miami Sylvester Comprehensive Cancer Center β Coral Gables, Florida
Chronic Lymphocytic Leukemia
View Study & Checklist βT Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
π Memorial Sloan Kettering Monmouth (Limited Protocol Activities) β Middletown, New Jersey
Myeloid Diseases
View Study & Checklist βProvision of TCRΞ³Ξ΄ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in NaΓ―ve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
π St. Jude Children's Research Hospital β Memphis, Tennessee
Acute Lymphoblastic Leukemia (ALL)
View Study & Checklist βA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
π City of Hope β Duarte, California
Multiple Myeloma
View Study & Checklist βAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
π National Institutes of Health Clinical Center β Bethesda, Maryland
Metastatic Solid Cancers
View Study & Checklist βModified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
π UCLA / Jonsson Comprehensive Cancer Center β Los Angeles, California
CD19 Positive
View Study & Checklist βHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
π Mayo Clinic Arizona β Phoenix, Arizona
Acute Lymphoblastic Leukemia
View Study & Checklist βIbrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Anemia
View Study & Checklist βHelical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
π City of Hope Medical Center β Duarte, California
Leukemia
View Study & Checklist βVenetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
π M D Anderson Cancer Center β Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist βA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
π Highlands Oncology Group ( Site 5205) β Springdale, Arkansas
Chronic Lymphocytic Leukemia
View Study & Checklist βOptimizing PTCy Dose and Timing
π National Institutes of Health Clinical Center β Bethesda, Maryland
Graft Versus Host Disease
View Study & Checklist βA Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
π University of Arkansas β Little Rock, Arkansas
Multiple Myeloma
View Study & Checklist βSorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
π M D Anderson Cancer Center β Houston, Texas
Recurrent Acute Myeloid Leukemia
View Study & Checklist βA Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
π UCI Sue & Bill Gross Stem Cell Research Center β Irvine, California
Multiple Sclerosis
View Study & Checklist β